Estimating Eligibility for GLP ‐1 Receptor Agonists for Chronic Weight Management and Cardiovascular Disease in Australia: Cross‐Sectional Analysis of National Health Survey Data
Medical Journal of Australia · 2026
DOI: 10.5694/mja2.70253 ↗Kurz gefasst
Fachartikel in der Zeitschrift Medical Journal of Australia, 2026. Verfasst von Jasmin Castrillon und 7 weiteren Autor:innen. Beteiligte Einrichtung: University of Melbourne, Melbourne, Victoria, Australia. Hauptthemen laut MEDLINE: Cardiovascular Diseases, Glucagon-Like Peptide-1 Receptor Agonists, Obesity, Overweight. Die Arbeit nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Objective
To estimate population‐level eligibility for glucagon‐like peptide‐1 receptor agonist (GLP‐1RA) medications among adults in Australia, according to Therapeutic Goods Administration‐approved indications for chronic weight management and secondary prevention of cardiovascular disease in individuals with overweight or obesity. Study Type Cross‐sectional analysis of data from the Australian Bureau of Statistics 2022 National Health Survey. Setting, Participants Non‐pregnant adults aged ≥ 18 years who were residents of Australia living in a private dwelling. Main Outcome Measures Total number of adults eligible for GLP‐1RA medications according to approved indications for chronic weight management and secondary prevention of cardiovascular disease in individuals with overweight or obesity, across subgroups defined by body mass index, weight‐related comorbidities and/or sociodemographic factors.
Results
Overall, 39.7% (95% confidence interval [CI], 38.4%–41.0%) of adults were eligible for GLP‐1RA use for chronic weight management, accounting for 7.8 million (95% CI, 7.6–8.1 million) individuals. Among those eligible, 2.9 million (95% CI, 2.7–3.1 million) adults had no weight‐related comorbidities, 3.3 million (95% CI, 3.1–3.4 million) adults had one weight‐related comorbidity and 1.7 million (95% CI, 1.6–1.8 million) adults had at least two weight‐related comorbidities. The proportion of adults eligible under this indication varied across clinical and sociodemographic factors. Among those eligible under the chronic weight management indication, up to 338.9 thousand (95% CI, 271.3–406.5 thousand) adults also met the indication criteria for secondary prevention of cardiovascular disease.
Conclusion
About 7.8 million Australian adults are eligible to access GLP‐1RAs for chronic weight management, with up to 338.9 thousand adults also qualifying according to the indication for established cardiovascular disease. This study provides a valuable reference for policymakers to understand the number of adults in Australia who may access GLP‐1RA medications based on approved indication criteria and under various coverage scenarios.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- University of Melbourne, Melbourne, Victoria, Australia.
- St Vincent's Hospital Melbourne, Melbourne, Victoria, Australia.
- Monash University, Melbourne, Victoria, Australia.
- Bayside Health (Alfred Care Group), Melbourne, Victoria, Australia.
ORCID-Profile: Jasmin Castrillon, Peter F Choong, Michelle M Dowsey
Zitieren
APA
Castrillon, J., Schilling, C., Thuraisingam, S., Hii, M. W., Sumithran, P., Choong, P. F., Dowsey, M. M., & Shadbolt, C. (2026). Estimating Eligibility for GLP ‐1 Receptor Agonists for Chronic Weight Management and Cardiovascular Disease in Australia: Cross‐Sectional Analysis of National Health Survey Data. Medical Journal of Australia. https://doi.org/10.5694/mja2.70253
Vancouver
Castrillon J, Schilling C, Thuraisingam S, Hii MW, Sumithran P, Choong PF, et al. Estimating Eligibility for GLP ‐1 Receptor Agonists for Chronic Weight Management and Cardiovascular Disease in Australia: Cross‐Sectional Analysis of National Health Survey Data. Medical Journal of Australia. 2026. doi:10.5694/mja2.70253
BibTeX
@article{Castrillon2026,
author = {Castrillon, Jasmin and Schilling, Chris and Thuraisingam, Sharmala and Hii, Michael W and Sumithran, Priya and Choong, Peter F and Dowsey, Michelle M and Shadbolt, Cade},
title = {Estimating Eligibility for GLP ‐1 Receptor Agonists for Chronic Weight Management and Cardiovascular Disease in Australia: Cross‐Sectional Analysis of National Health Survey Data},
journal = {Medical Journal of Australia},
year = {2026},
doi = {10.5694/mja2.70253}
}
EUVIMED